09:43 AM EST - Antibe Therapeutics Inc : Today filed its financial and operating results for the fiscal year ended March 31, 2021. Revenue totaled $9.7 million, a negligible increase compared to the fiscal 2020 period. All revenue was due to the Company’s subsidiary, Citagenix; sales were adversely affected by the COVID-19 crisis in fiscal Q1 but recovered strongly in fiscal Q2 through Q4. Net loss amounted to $26.3 million ($0.70 per share), compared to $19.3 million ($0.71 per share) for fiscal 2020. Antibe Therapeutics Inc
shares T.ATE are trading unchanged at $3.91.
